Early-stage biotech ALSP, Inc. is a private San Diego biotech with a small team focused on neurodegenerative drug discovery, presenting an opportunity to engage in partnerships, grant support programs, and early collaboration discussions to accelerate pipeline development.

Targeted drug discovery The company concentrates on protease targets in the brain to inhibit harmful peptides, indicating potential sales angles for contract research, assay development, CRO support, and potential licensing discussions for proprietary screening platforms.

Neurodegenerative focus With interest in traumatic brain injury, Alzheimer's, Huntington's, Parkinson's, and MS, there is a broad addressable market for collaboration on preclinical models, biomarkers, and translational research services.

Funding signal Current revenue is under one million with modest funding of about 1.1 million, suggesting a readiness to explore strategic partnerships, non-dilutive funding opportunities, and service-based collaborations to accelerate milestones.

Tech & readiness Lean tech stack and small team imply agility and potential interest in integrated digital CRO solutions, data management, and cloud-enabled collaboration tools to streamline research workflows and external partnerships.